May 19, 2016

MediWound's NexoBrid® Highlighted in "Best Oral Presentation" at the British Burn Association 49th Annual Conference and Scientific Meeting

Award-winning Abstract Underscores Role of NexoBrid in Direct Assessment of Burn Severity

YAVNE, Israel, May 19, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBrid® in the direct assessment of burn severity was selected as "Best Oral Presentation" at the British Burn Association's (BBA) 49th Annual Conference and Scientific Meeting. The BBA conference was held in Newcastle, England May 11-13, 2016, and the presentation, titled "Burn Depth Assessment: Laser Doppler Imaging (LDI) vs. Enzymatic Debridement," was delivered by Dr. Hendrik Hoeksema, Department of Plastic Surgery, University Ziekenhuis Hospital, Gent Belgium.

The presentation reported on 12 patients with deep dermal and full-thickness burns, who on clinical assessment were first scanned with laser Doppler Imaging (LDI) and then underwent selective enzymatic eschar removal with NexoBrid. The study concluded that "LDI predictions were accurate in terms of healing time but early enzymatic [NexoBrid] eschar removal allowed for a more precise burn depth assessment of the deep dermal and full thickness wounds by direct visual assessment of the debrided wound bed, resulting in a more informed decision on further treatment."

"We are very excited that for the second consecutive year an abstract highlighting NexoBrid's merits is awarded the best presentation in a leading burn conference. The study was conducted at the well-recognized Gent burn center that led the development and use of the LDI technology for wound severity diagnosis and describes NexoBrid's ability to facilitate direct, more precise assessment of wound severity by selectively removing the dead tissue soon after admission, thus allowing burn specialists to make better informed treatment decisions," noted Gal Cohen, President and Chief Executive Officer of MediWound. "Using NexoBrid to debride the wound and allow for a more accurate assessment of wound severity can also play a critically important role in Mass Casualty Incidences, where it is imperative to assess burn severity promptly for prioritization and referral. These supportive data are very encouraging and it is an honor to have NexoBrid recognized before a large audience of burn specialists. We look forward to continuing to foster and support evidence-based medicine to advance burn care."

About the British Burn Association

The British Burn Association, formed in 1968, is a National non-profit organization that enjoys charitable status. Membership is not only available to physicians, surgeons, scientists, nurses, members of ancillary medical services and non-medical workers actively engaged in some aspect of the care of the burned patient, but also to persons interested in playing an active part in attempting to reduce the incidence and noxious effect of burning injury. The Association holds an Annual Scientific Meeting at which a wide variety of original papers are presented. The meetings normally conclude with the Wallace Lecture, which is delivered by a speaker who has made outstanding contributions to the field of burn care.

About NexoBrid

NexoBrid is an easy-to-use, topically-applied product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissues. NexoBrid received marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, is commercially available in Europe and Israel and will be launched in Argentina in the coming months. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or "debridement" is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard of care, burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue necessitating further surgical treatments. The U.S. Phase 3 clinical trial and registration process for NexoBrid is being funded in whole or in part with federal funds under a contract with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.

About MediWound Ltd.

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel, with plans for a launch in Argentina. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues.

MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®. In two Phase 2 studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com.

Contacts:	Anne Marie Fields
Sharon Malka	Senior Vice President
Chief Financial and Operations Officer	LHA
MediWound	212-838-3777
ir@mediwound.co.il	afields@lhai.com

Primary Logo

Source: MediWound Ltd.

News Provided by Acquire Media